Market Overview

Singular Research Reiterates BioSante Pharmaceuticals Buy, Maintains PT


Singular Research reiterated its BioSante Pharmaceuticals (NASDAQ: BPAX) Buy rating and maintained its $7 price target in a research report published today.

In the report, Singular Research states, "The Phase III clinical trials for LibiGel® are completed and the company is compiling the data. Management has announced it will release a data summary in December 2011."

Shares of BioSante Pharmaceuticals were trading at $2.58 at the time of posting, up 1.57% from Monday's market close.

Posted-In: Singular ResearchAnalyst Color Reiteration Analyst Ratings


Related Articles (BPAX)

View Comments and Join the Discussion!

Latest Ratings

PSInitiates Coverage On40.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

J.P. Morgan Downgrades Comtech Telecommunications, Lowers PT

Bank of America Names John Bottega Chief Data Officer